Publication date: Mar 07, 2019
This post was originally published on this site Encouraging new preclinical data on AMT-130, uniQure’s experimental gene therapy candidate for Huntington’s disease, were presented at the 14th Annual Huntington’s disease Therapeutics Conference. -Findings from our preclinical studies illustrate the therapeutic potential of AMT-130 in restoring function to damaged brain cells in Huntington’s disease and providing a safe and sustained reduction of mutant huntingtin protein with a gene therapy candidate that could be applicable to a broad patient population,” Sander van Deventer, MD, PhD, chief scientific officer at uniQure, said in a press release. -uniQure’s neuroimaging translational studies in non-human primates and Huntington’s disease patients shows the importance of careful, individualized neurosurgical planning and meticulous dosing parameters in delivering gene therapy products to the brain,” said Joseph J. Higgins, MD, vice president, clinical development at uniQure. In another poster titled -Virtual neurosurgical planning demonstrates the safety of deep brain gene delivery in patients with early manifest HD,” researchers used high-resolution magnetic resonance imaging (MRI) to identify the correct path through which they could guide micro-catheters for the targeted delivery of AMT-130 in affected regions of the brain. Scientific presentations by uniQure also included a talk by Pavlina Konstantinova, PhD, vice president, new therapeutic target discovery at uniQure, titled -Gene Therapy for Huntington’s Disease: Silencing the Villain,” as well as two more posters -Sustained mutant huntingtin lowering in the brain and cerebrospinal fluid of Huntington disease minipigs mediated by AAV5-miHTT gene therapy” and -Transfer of therapeutic miRNAs within extracellular vesicles secreted from Huntington’s disease iPSC-derived neurons. ” The post Gene Therapy Candidate AMT-130 Shows Promise in Preclinical Findings appeared first on Huntington’s Disease News.
- Huntington’s disease therapeutics conference 2019 – Day 1
- Phase 3 Trial of RG6042 Will Gauge Potential of Gene-silencing Approaches for Huntington’s, Other Diseases
- Huntington’s disease therapeutics conference 2019 – Day 2